Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment

被引:108
作者
Berenguer, Marina [1 ,2 ]
Schuppan, Detlef [3 ,4 ]
机构
[1] Univ Valencia, Dept Med, Hepatol & Liver Transplantat Unit, La Fe Hosp, E-46003 Valencia, Spain
[2] Inst Salud Carlos III, Natl Network Ctr Hepatol & Gastroenterol Res, CIBEREHD, Madrid, Spain
[3] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 1, D-55116 Mainz, Germany
[4] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA
关键词
Antifibrotic; Biopsy; Cirrhosis; Collagen; Elastography; Fibrosis; HCV; Hepatic stellate cell; Interferon; Liver; Macrophage; NAFLD; Post-transplant; Progression; Second hit; T cell; TGFbeta; Serum marker; Transplantation; VENOUS-PRESSURE GRADIENT; VIRUS CORE PROTEIN; OPEN-LABEL SERIES; SUSTAINED VIROLOGICAL RESPONSE; TRANSPLANT RECIPIENTS; ANTIVIRAL THERAPY; PEGYLATED-INTERFERON; TRANSIENT ELASTOGRAPHY; STELLATE CELLS; CLINICAL-IMPLICATIONS;
D O I
10.1016/j.jhep.2012.12.014
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Liver fibrosis results from an excessive wound healing response in most chronic liver diseases, such as hepatitis C. Despite great advances in antiviral therapy in recent years, progressive liver fibrosis remains a major problem for patients with recurrent hepatitis C after liver transplantation. Liver biopsy remains a central tool in the management of HCV-positive liver transplant recipients, but reliable non-invasive methods for the assessment of liver fibrosis, such as ultrasound elastography, are increasingly being incorporated in the management of post-transplant patients, helping predict prognosis, guide treatment decisions, and stratify patients for emerging antifibrotic therapies. In this manuscript, we will review the natural history as well as tools to monitor fibrosis progression in the HCV-positive liver transplant recipient, the mechanisms underlying rapid fibrosis progression in up to 30% of these patients, the effect of antiviral therapies and highlight promising antifibrotic approaches. (c) 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1028 / 1041
页数:14
相关论文
共 160 条
  • [71] Lipid Metabolism and Liver Disease in Hepatitis C Viral Infection
    Koike, Kazuhiko
    Tsutsumi, Takeya
    Yotsuyanagi, Hiroshi
    Moriya, Kyoji
    [J]. ONCOLOGY, 2010, 78 : 24 - 30
  • [72] Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production
    Korenaga, M
    Wang, T
    Li, YC
    Showalter, LA
    Chan, TS
    Sun, JR
    Weinman, SA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (45) : 37481 - 37488
  • [73] Hepatitis C Virus-Infected Women Have a Higher Risk of Advanced Fibrosis and Graft Loss After Liver Transplantation than Men
    Lai, Jennifer C.
    Verna, Elizabeth C.
    Brown, Robert S., Jr.
    O'Leary, Jacqueline G.
    Trotter, James F.
    Forman, Lisa M.
    Duman, Jeffrey D.
    Foster, Richard G.
    Stravitz, R. Todd
    Terrault, Norah A.
    [J]. HEPATOLOGY, 2011, 54 (02) : 418 - 424
  • [74] Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection
    Lange, Christian M.
    Moradpour, Darius
    Doehring, Alexandra
    Lehr, Hans-Anton
    Muellhaupt, Beat
    Bibert, Stephanie
    Bochud, Pierre-Yves
    Antonino, Anca T.
    Pascual, Manuel
    Farnik, Harald
    Shi, Ying
    Bechstein, Wolf Otto
    Moench, Christian
    Hansmann, Martin-Leo
    Sarrazin, Christoph
    Loetsch, Joern
    Zeuzem, Stefan
    Hofmann, Wolf-Peter
    [J]. JOURNAL OF HEPATOLOGY, 2011, 55 (02) : 322 - 327
  • [75] Magnetic Resonance Elastography and Biomarkers to Assess Fibrosis From Recurrent Hepatitis C in Liver Transplant Recipients
    Lee, Victoria S.
    Miller, Frank H.
    Omary, Reed A.
    Wang, Yi
    Ganger, Daniel R.
    Wang, Edward
    Rao, Sambasiva
    Levitsky, Josh
    [J]. TRANSPLANTATION, 2011, 92 (05) : 581 - 586
  • [76] Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated Interferon
    Levitsky, Josh
    Fiel, Maria Isabel
    Norvell, John P.
    Wang, Edward
    Watt, Kymberly D.
    Curry, Michael P.
    Tewani, Sumeet
    McCashland, Timothy M.
    Hoteit, Maarouf A.
    Shaked, Abraham
    Saab, Samuel
    Chi, Amanda C.
    Tien, Amy
    Schiano, Thomas D.
    [J]. GASTROENTEROLOGY, 2012, 142 (05) : 1132 - +
  • [77] HIV increases HCV replication in a TGF-β1-dependent manner
    Lin, Wenyu
    Weinberg, Ethan M.
    Tai, Andrew W.
    Peng, Lee F.
    Brockman, Mark A.
    Kim, Kyung-Ah
    Kim, Sun Suk
    Borges, Carolina B.
    Shao, Run-Xuan
    Chung, Raymond T.
    [J]. GASTROENTEROLOGY, 2008, 134 (03) : 803 - 811
  • [78] HIV and HCV Cooperatively Promote Hepatic Fibrogenesis via Induction of Reactive Oxygen Species and NFκB
    Lin, Wenyu
    Wu, Guoyang
    Li, Shaoyong
    Weinberg, Ethan M.
    Kumthip, Kattareeya
    Peng, Lee F.
    Mendez-Navarro, Jorge
    Chen, Wen-Chi
    Jilg, Nikolaus
    Zhao, Hong
    Goto, Kaku
    Zhang, Leiliang
    Brockman, Mark A.
    Schuppan, Detlef
    Chung, Raymond T.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (04) : 2665 - 2674
  • [79] Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease
    Lonardo, A
    Adinolfi, LE
    Loria, P
    Carulli, N
    Ruggiero, G
    Day, CP
    [J]. GASTROENTEROLOGY, 2004, 126 (02) : 586 - 597
  • [80] Oval cell numbers in human chronic liver diseases are directly related to disease severity
    Lowes, KN
    Brennan, BA
    Yeoh, GC
    Olynyk, JK
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (02) : 537 - 541